Key Events This Week
23 Mar: New 52-week low at Rs.6.03
24 Mar: Further decline to Rs.6.00, extending downtrend
25 Mar: Stock hits Rs.5.70, continuing slide despite Sensex gains
27 Mar: Hits fresh 52-week low at Rs.5.53 and lower circuit
23 March 2026: Stock Hits 52-Week Low at Rs.6.03 Amid Market Slump
Vivimed Labs Ltd’s share price declined sharply to Rs.6.03 on 23 March, marking a fresh 52-week low and a 4.42% drop from the previous close. This decline occurred alongside a broader market sell-off, with the Sensex falling 3.13%. The stock’s fall was more pronounced than the Pharmaceuticals & Drugs sector’s 3.14% decline, signalling company-specific pressures.
The stock’s price fell below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained bearish momentum. Financially, Vivimed Labs faces significant challenges, with a high debt-to-equity ratio of 9.51 times and a debt-to-EBITDA ratio of 12.57 times, reflecting heavy leverage and limited earnings capacity to service debt. Profitability remains weak, with an average ROE of 1.75% and a 386% profit decline over the past year, despite a flat stock price over the same period.
24 March 2026: Continued Decline to Rs.6.00 Despite Sensex Recovery
The downward trend persisted on 24 March, with the stock slipping further to Rs.6.00, a 1.16% decline on the day. This extended the losing streak to four consecutive sessions, accumulating a 9.09% loss over this period. The Sensex showed volatility, initially rising by 1.95% but closing down 1.13%, yet Vivimed Labs underperformed both the benchmark and its sector.
Technical indicators remained bearish, with the stock trading below all major moving averages. The company’s Mojo Score of 17.0 and a Strong Sell grade reflect deteriorating fundamentals and technical outlook. Negative EBITDA and flat December 2025 results further dampened investor confidence.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
25 March 2026: Stock Falls to Rs.5.70 Despite Sensex Gains
On 25 March, Vivimed Labs Ltd’s stock price dropped to Rs.5.70, a 2.84% decline, marking yet another 52-week low. This occurred even as the Sensex gained 1.93%, highlighting the stock’s divergence from broader market trends. The stock’s underperformance was notable, trading below all key moving averages and signalling persistent bearishness.
Financially, the company’s elevated leverage and negative EBITDA continued to weigh on sentiment. The average ROE of 1.75% and a 386% profit decline over the past year underscore the fundamental challenges. Despite the stock’s one-year flat return, the deteriorating earnings profile and technical weakness have driven the downtrend.
27 March 2026: Fresh 52-Week Low and Lower Circuit Hit at Rs.5.53
Vivimed Labs Ltd’s stock closed at Rs.5.53 on 27 March, down 4.98%, hitting a fresh 52-week low and triggering the lower circuit limit at Rs.5.55. This marked the sixth consecutive session of losses, with the stock declining 16.21% over this period. The heavy selling pressure overwhelmed demand, resulting in the price freeze at the lower circuit band.
The stock’s underperformance was stark compared to the Pharmaceuticals & Drugs sector’s 0.32% decline and the Sensex’s 1.08% fall. Technical indicators remained bearish, with the stock trading below all major moving averages and exhibiting weak momentum across daily, weekly, and monthly charts.
Investor participation increased, with delivery volumes surging 66.89% above the five-day average on 25 March, indicating heightened trading activity amid volatility. However, the unfilled supply at the lower circuit level reflected panic selling and a lack of buying interest.
Vivimed Labs Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.6.06 | -4.42% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.5.99 | -1.16% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.5.82 | -2.84% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.5.53 | -4.98% | 32,935.19 | -2.11% |
Key Takeaways from the Week
The week’s trading activity for Vivimed Labs Ltd was dominated by a persistent downtrend, with the stock falling 12.78% against a 1.46% decline in the Sensex. The stock’s multiple 52-week lows and eventual lower circuit hit highlight intense selling pressure and deteriorating investor confidence.
Financially, the company’s high leverage, reflected in a debt-to-equity ratio of 9.51 times and a debt-to-EBITDA ratio of 12.57 times, remains a significant concern. Profitability metrics are weak, with an average ROE of 1.75% and a 386% decline in profits over the past year. Negative EBITDA and flat recent earnings further exacerbate the risk profile.
Technically, the stock trades below all major moving averages, with bearish signals from weekly and monthly MACD, RSI, and Bollinger Bands. The increased delivery volumes amid falling prices suggest heightened volatility and potential panic selling, especially given the micro-cap status and predominance of non-institutional investors.
Conclusion: A Challenging Outlook Amidst Persistent Headwinds
Vivimed Labs Ltd’s share price performance this week underscores the significant challenges facing the company. The combination of weak financial fundamentals, elevated leverage, negative earnings trends, and bearish technical indicators has culminated in a steep price decline and heightened volatility. The stock’s underperformance relative to the Sensex and its sector reflects company-specific risks that continue to weigh on investor sentiment.
Absent any near-term positive catalysts or fundamental improvements, the stock is likely to remain under pressure. Investors should remain cautious and monitor upcoming corporate developments closely, given the micro-cap nature of the stock and its sensitivity to market fluctuations.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
